# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹1,742.8 Cr** Q4 (+22%) · **₹6,430.7 Cr** FY26 (+14.5%) * **Adj. EBITDA:** **₹524.4 Cr** Q4 (30% Margin) · **₹1,682.6 Cr** FY26 (26% Margin) * Adj. PAT: ₹3,667 Mn Q4 (21% Margin) · ₹10,455 Mn FY26 (16% Margin) * **Gross Margin:** **66%** Q4 (+30 bps) · **65%** FY26 (+230 bps) * **Cash & Debt:** **₹3,359.1 Cr** Cash & Equiv. · **₹243.4 Cr** External Debt (Cenexi) ## B. Revenue & Growth * **Record Performance:** Achieved highest-ever quarterly revenue and EBITDA, underpinned by volume expansion in the base business and new product launches. * **Cenexi Recovery:** Full-year growth was significantly bolstered by a meaningful turnaround in the Cenexi segment. * **Revenue Mix:** Quarterly performance included a **9% profit share** and **6% milestone revenue** contribution. ## C. Margins & Profitability * **Operating Leverage:** Significant year-on-year margin expansion driven by cost efficiencies and the commercialization of two new production lines. * **Strategic Product Mix:** Margins supported by the high-margin launch of **Dalba** and long-term CDMO contracts in specialized areas like nanotechnology. * **Tax Outlook:** Management expects the current **30% effective tax rate** to decrease as Cenexi’s profitability improves. * **Future Guidance:** The company aims to sustain margins above **25%** by balancing high-volume operating leverage with high-value complex manufacturing. ## D. Cash Flow & Capex * **Liquidity Management:** Cash flow from operations rose to **₹1,031.4 Cr**, aided by a shortened cash conversion cycle of **164 days**. * **Capital Allocation:** Executing a **INR 2,000 Cr** multi-year capex plan, with **INR 300 Cr** earmarked for the current year and **INR 500 Cr** for FY2027. * **Investment Focus:** Spending is prioritized toward India-based capacity expansion and high-value complex product strategies. --- # 2. Operating Segments & Markets ## A. Key Figures * CDMO Growth: 33% FY '26 * **B. S. Market Revenue:** **₹971.6 Cr** Q4 (+26%) · **₹3,318.1 Cr** FY (+11%) * **Cenexi Revenue:** **€4.5 Cr** Q4 (+4%) · **€18.2 Cr** FY (+11%) * **Cenexi EBITDA:** **€0.1 Cr** Q4 (Turnaround) · **+€1.6 Cr** FY improvement * **Base Business EBITDA Margin (ex-Cenexi):** **41%** Q4 · **38%** FY * **Other Markets (FY):** **₹324.9 Cr** Europe/Regulated (+11%) · **₹651.1 Cr** RoW (+7%) · **₹267.2 Cr** India ## B. CDMO Segment Performance * **Strategic Growth Engine:** Robust double-digit expansion driven by new launches (Dalbavancin), tender wins, and high-margin project delivery. * **Pipeline Commercialization:** Major project slated for H2 FY '28 with **USD 2.5–3.0 Cr** annual potential; CMS European project to commercialize in **Q3 current year**. * **Site-Specific Momentum:** Production ramp-up of vaccines and ophthalmic gels at Hérouville and a large hormonal drug contract at Braine-l'Alleud underpin future volumes. * **Operational Leverage:** High margins in the final quarter were bolstered by the commencement of new GPO contracts and improved capacity utilization. ## C. U.S. Market Trends * **Dominant Market Position:** Sustained growth fueled by **31 new product launches** and increased volume pull-through from GPO contracts. * **Incremental Upside:** New launches projected to add **INR 200 Cr** to base business, with further tailwinds expected from ongoing **D. S. drug shortages**. ## D. Cenexi Business Turnaround * **Path to Profitability:** Achieved second consecutive EBITDA-positive quarter following workforce rationalization and contract renegotiations. * **Margin Outlook:** Management targets **mid-to-high single-digit** EBITDA margins by end of **FY 2027** through operational efficiencies and new production lines. * **Operational Recovery:** Growth primarily led by site improvements at Hérouville and Fontenay, marking a successful integration phase. --- # 3. Product Portfolio & Pipeline ## A. Key Figures * **R&D Expenditure:** **₹223 Cr** FY26 (5% of base revenue) · **₹50.6 Cr** Q4 (4% of base revenue) * **B. S. Market Activity:** **24** ANDA Filings · **28** Approvals · **31** Product Launches * **GLP-1 Capacity:** **14 Crore Units** (Cartridges) * **New Launch Contribution:** **$40 Million** (MVI portfolio, GPO contract, and annualized Q3 launches) ## B. Complex Injectables & Launch Momentum * **Strategic Launch Execution:** Strong initial demand for Dalbavancin in the U.S. and Europe; growth is underpinned by a Vizient contract rather than inventory loading, with sales expected to scale over the next four quarters. * **Portfolio Diversification:** The newly launched multivitamin (MVI) portfolio is positioned as a steady revenue stream with significant growth contributions projected for **FY '27** and beyond. * **Pipeline Strategy:** Future momentum is tied to the ramp-up of CDMO partnerships and a transition from traditional vials to high-value **device-based formats**. ## C. GLP-1 Contract Status * **Aggressive CDMO Positioning:** Gland is strictly a CDMO partner for Liraglutide, Semaglutide, and Tirzepatide; currently holds **8 signed contracts** with an additional **6 to 7** in the immediate pipeline. * **Conservative Guidance:** Management is excluding all GLP-related revenue from current financial guidance and capacity utilization estimates, treating the sector as pure "potential upside." * **Long-term Horizon:** While exhibit batches and filings begin this year, significant volume ramp-up is back-ended **post-2030** to coincide with U.S. patent expirations. ## D. R&D & Therapy Mix * **Off-Balance Sheet Innovation:** Beyond the reported R&D spend, the company is executing **15 co-development projects** and a Chinese in-licensing program for liposomal products not captured in primary R&D metrics. * **Specialized Manufacturing:** Development programs are shifting toward **hormone products** at Cenexi sites to exploit global supply shortages and limited manufacturing capacity in that niche. * **Technical Focus:** Investment remains concentrated on complex injectables, peptides, and specialty delivery platforms to maintain a differentiated, high-value portfolio. --- # 4. Manufacturing & Capacity ## A. Key Figures * **Cenexi Utilization:** **90%–100%** Fontenay/Osny sites · **50%–60%** Other sites * **GLP-1 Capacity:** **140 million units** Total capacity, with insulin use filling 30–40 million units * **Efficiency Margin Impact:** **1%–2%** Improvement from yield/sourcing/energy * New Ampoule Capacity: 30 million units at Fontenay site by 2027 ## B. Capacity Utilization Rates * **Operating Leverage:** Performance driven by robust volume growth and improved utilization across key lines, optimizing cost structures. * **Strategic Backfilling:** To utilize the new **combo line** ahead of the GLP-1 ramp-up, an insulin contract will occupy **3 crore to 4 crore units** of capacity over the coming years. * **Utilization Outlook:** While core sites operate at near-full capacity, others await tech transfers; GLP-1 utilization remains contingent on the timing of international regulatory approvals. ## C. Production Line Expansion * **Fontenay Site Scaling:** Addressing supply shortages by adding and replacing lines, including a new ampoule line ramping up now and another scheduled for **August 2026**. * **Portfolio Diversification:** Board approval secured for a new **ophthalmic line with suspension capabilities** and an expansion into **blow-fill-seal technology** to bypass current constraints. * **Long-term GLP-1 Strategy:** Capacity expanded significantly to **14 crore units** to secure a major commercial launch window projected for **2030**. * **Near-term Commissioning:** Three additional lines are set to go live across the current and subsequent quarters to meet immediate demand. ## D. Operational Efficiency & Technology * **Cenexi Profitability Pivot:** Margin expansion strategy focuses on replacing low-value products with high-value launches and efficiency gains rather than pure volume growth. * **Cost Optimization:** Initiatives include increasing batch sizes for new contracts, hedging European power costs, and acquiring a **solar plant** in India to boost renewable energy mix. * **Future-Proofing:** Limited capital expenditure currently directed toward biologics/biosimilars, focusing instead on small-scale technical know-how and **AI/automation** investments. --- # 5. Strategic Initiatives & M&A ## A. Strategic Integration & Synergies * **Unified Platform Evolution:** Integration of Cenexi and Gland Pharma has enabled a unified market approach, securing larger multi-geography contracts and new global customer acquisitions. * **Cross-Selling Momentum:** Gland is currently leveraging synergies by signing **5 to 6 products** with Cenexi’s existing client base to drive group-level growth. * **Technological Expansion:** The acquisition provides specialized capabilities previously unavailable in India, specifically the manufacture of **sex hormones** and **controlled substances**. * **Revenue Realization Timeline:** Financial impact from synergies is projected for **FY 2028**, though initial launches from **three signed Marketing Authorizations (MAs)** may begin as early as **Q3 of the current year**. ## B. Leadership & Long-term Strategy * **Executive Search:** Management is actively recruiting a new CEO with specific expertise in the **CDMO and biologics** sectors to lead the next growth phase. * **Portfolio Diversification:** Long-term strategy is centered on high-barrier segments including **complex injectables, liposomals, and biosimilars**. * **European Market Foothold:** Cenexi serves as a strategic CDMO hub in Europe and acts as a critical **releasing entity** for Gland’s product portfolio within the region. --- # 6. Pricing & Operational Risks ## A. Key Figures * **Logistics Cost Impact:** **1% to 2%** of revenue * **Supplier Price Hikes:** **5% to 6%** for vials and glass * **Total Cost Impact:** **1% to 2%** from input inflation ## B. Geopolitical & Macro Impact * **Regional Headwinds:** Geopolitical instability in the Middle East led to a temporary cessation of shipments to **Saudi Arabia**, though management anticipates a recovery once conditions stabilize. * **Logistics Resilience:** Freight cost escalations are expected to have a negligible effect on the bottom line due to established **cost-sharing agreements** with partners. ## C. Input Cost & Currency Exposure * **Supply Chain Inflation:** Conflict-driven price hikes in raw materials (glass/vials) are projected to result in a modest increase in the overall cost structure. * **Forex Risk Mitigation:** The company maintains a **natural hedging strategy** for its core operations, while the Cenexi unit remains insulated through Euro-denominated revenue and cost alignment. --- # 7. Guidance & Outlook ## A. Key Figures * **Consolidated Revenue Growth (FY27):** **12% to 13%** Constant Currency (Excl. GLP-1) * Cenexi Revenue (FY27): ~€200M (~₹150 Cr excl. forex) * **Base Business Growth (FY27):** **₹650 Cr** (Excl. forex) · **$4 Cr to $5 Cr** New CDMO Contracts * **EBITDA Margin Guidance:** **33% to 35%** Base Business · **25% to 26%** Consolidated * **Long-term Growth (4-Year):** **15%** Consolidated CAGR ## B. FY '27 Revenue Targets * **Low-Risk Guidance Profile:** The projected double-digit growth is underpinned by existing CDMO contracts and products already approved or awaiting patent expiration, providing high visibility. * **Conservative Modeling:** Management has excluded all potential upside from **GLP-1 products** due to regulatory and market timing uncertainties. * **Currency Tailwinds:** While guidance is set at constant currency, management anticipates a potential **5% to 6%** upside from favorable **USD-INR and Euro-INR** exchange rates. ## C. Medium-term Margin Profile * **Profitability Recovery:** Management reaffirmed a mid-term goal of reaching mid-teen EBITDA for the Cenexi unit through operational integration and capacity scaling. * **Consolidated Outlook:** Group margins are expected to stabilize in the mid-20s, supported by the high-margin profile of the base business. ## D. Long-term Growth Step-up * **Strategic Growth Inflection:** A major performance step-up is forecasted for **FY 2029**, with revenue growth potentially reaching **19% to 20%** as large-scale complex products launch. * **Product Pipeline Drivers:** Sustained momentum is tied to a robust CDMO pipeline, Ready-to-Use (RTU) bags, and complex injectable suspension products. * **Phased Scaling:** Growth is expected to accelerate from the current guidance to **15%** in **FY 2028**, driven by specific product launches tied to settlement dates.